Daniel J. Pratt, PE

Takeda Pharmaceutical International Co.
Director Engineering and PM
Dan is currently Director of Engineering and Project Management in Takeda Pharmaceutical’s Global Oncology and Biologics Group. One of his favorite parts of his current responsibilities is searching for new and innovative technologies to advance Takeda’s manufacturing processes. Dan is currently working with Takeda’s Grange Castle Ireland site to build a high potent facility to manufacture Ninlaro®, which treats patients with multiple myeloma. Dan has over twenty-five years of experience developing and manufacturing both small molecule and biologics pharmaceuticals, from drug substance through secondary packaging. Dan has a broad scope of experience, including: managing CMOs, leading technical transfer, constructing and commissioning facilities, process and equipment validations, and facilitating product and process improvements. Dan has co-founded the start up Neurological Models Inc., as well as worked for the multi-national companies DuPont and Bristol Myers Squibb. Dan is currently a member ISPE Boston Chapter’s Educational Program Committee.

Related Articles

Proof of Closure: Life Cycle of Closed Systems
Special Reports
Proof of Closure: Life Cycle of Closed Systems

This article was developed by members of the ISPE Biotechnology Community of Practice. The views and opinions are those of the authors and do not necessarily reflect the official policy or position of Hargrove Life Sciences, M+W, Novartis, Sandoz, Takeda, or any of their officers.